Q-omics provides the consensus-scored CCNB2P1 profile across patient tissues and cancer cell-line models. CCNB2P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCNB2P1 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, CCNB2P1 RNA expression shows 14,053 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where CCNB2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNB2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNB2P1 survival associations across molecular data types. CCNB2P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNB2P1 RNA expression–survival associations across cancer types. High CCNB2P1 expression shows unfavorable associations in HNSC, COAD, DLBC, ACC, PAAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCNB2P1 RNA expression.
This table summarizes CCNB2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCNB2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNB2P1 shows lower tumor expression in THCA and KIRP and higher tumor expression in UCEC, COAD, KICH and HNSC. The THCA box plot shows higher CCNB2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.063, t-test p < 0.001).
This table shows molecular features associated with CCNB2P1 in patient tissues and cancer cell lines. In patient samples, CCNB2P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
